Hanall Biopharma Co., Ltd. (KRX:009420)
South Korea · Delayed Price · Currency is KRW 61,100
+300 (0.49%)
Feb 26, 2026, 11:20 AM KST
Hanall Biopharma Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Net Income | 2,310 | -1,805 | 3,509 | 251.47 | 8,896 | 19,764 |
Depreciation & Amortization | 3,581 | 3,121 | 3,247 | 3,053 | 2,725 | 2,894 |
Loss (Gain) From Sale of Assets | -17.19 | 452.56 | 9.32 | -16.99 | 1,052 | 14.29 |
Asset Writedown & Restructuring Costs | - | - | 36.72 | - | - | 44.82 |
Loss (Gain) From Sale of Investments | -7.68 | -331.43 | -1,121 | 625.15 | 177.44 | - |
Loss (Gain) on Equity Investments | 91.21 | 99.53 | 62.12 | 45.39 | - | - |
Stock-Based Compensation | 349.52 | 584.26 | 1,623 | 1,875 | 1,617 | 794.3 |
Provision & Write-off of Bad Debts | 0.82 | -126.7 | 50.6 | 61.23 | -21.9 | -126.79 |
Other Operating Activities | 5,221 | 3,819 | 2,044 | 4,516 | 1,694 | -9,049 |
Change in Accounts Receivable | 3,623 | 2,367 | 8,168 | -2,466 | -5,919 | 4,306 |
Change in Inventory | -7,843 | -5,748 | -8,292 | -5,814 | -1,476 | -8,435 |
Change in Accounts Payable | 9,202 | -127.23 | 5,518 | 3,361 | -1,731 | 646.63 |
Change in Other Net Operating Assets | -2,642 | 7,055 | 14,789 | 19,774 | -6,174 | -9,924 |
Operating Cash Flow | 13,868 | 9,360 | 29,643 | 25,264 | 839.87 | 929.29 |
Operating Cash Flow Growth | 56.98% | -68.42% | 17.33% | 2908.10% | -9.62% | -95.47% |
Capital Expenditures | -1,397 | -1,642 | -2,412 | -2,830 | -4,606 | -2,562 |
Sale of Property, Plant & Equipment | 18.92 | - | - | 17 | 120.91 | 1.5 |
Sale (Purchase) of Intangibles | -15,331 | -21,427 | -6,786 | -4,847 | -4,396 | -4,827 |
Investment in Securities | -4,541 | -4,125 | -2,676 | -2,932 | 16,911 | 5,070 |
Other Investing Activities | -0 | -0 | -0 | - | -0 | -0 |
Investing Cash Flow | -21,167 | -27,493 | -11,887 | -10,592 | 8,030 | -2,318 |
Long-Term Debt Repaid | - | -942.18 | -813.51 | -698.88 | -715.25 | -587.67 |
Total Debt Repaid | -991.6 | -942.18 | -813.51 | -698.88 | -715.25 | -587.67 |
Net Debt Issued (Repaid) | -991.6 | -942.18 | -813.51 | -698.88 | -715.25 | -587.67 |
Issuance of Common Stock | 4,460 | 1,702 | - | - | 408.72 | 68.33 |
Repurchase of Common Stock | -3,221 | - | - | -10,005 | - | - |
Financing Cash Flow | 247.84 | 759.59 | -813.51 | -10,704 | -306.53 | -519.35 |
Foreign Exchange Rate Adjustments | 53.22 | 36.83 | -60.45 | 78.63 | 30.85 | -11.85 |
Miscellaneous Cash Flow Adjustments | 0 | 0 | 0 | - | - | - |
Net Cash Flow | -6,998 | -17,336 | 16,882 | 4,047 | 8,594 | -1,920 |
Free Cash Flow | 12,471 | 7,718 | 27,231 | 22,434 | -3,766 | -1,633 |
Free Cash Flow Growth | 76.35% | -71.66% | 21.38% | - | - | - |
Free Cash Flow Margin | 8.09% | 5.56% | 20.18% | 20.39% | -3.71% | -1.84% |
Free Cash Flow Per Share | 245.64 | 152.20 | 537.18 | 441.48 | -73.55 | -31.91 |
Cash Interest Paid | 80.75 | 70.97 | 63.86 | 39.45 | - | - |
Cash Income Tax Paid | - | 782.26 | 1,017 | 606.84 | 1,695 | 1,826 |
Levered Free Cash Flow | -7,744 | -26,378 | 4,850 | -17,027 | -665.94 | -4,687 |
Unlevered Free Cash Flow | -7,694 | -26,333 | 4,890 | -17,014 | -650.01 | -4,677 |
Change in Working Capital | 2,339 | 3,548 | 20,183 | 14,855 | -15,299 | -13,407 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.